Entry |
|
Name |
Idursulfase beta (INN); Idursulfase beta (genetical recombination) (JAN); Hunterase (TN) |
Formula |
C2689H4051N699O793S13
|
Exact mass |
59238.4522
|
Mol weight |
59275.00
|
Sequence |
SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ NAFAQQAVCA PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN FSTIPQYFKE NGYVTMSVGK VFHPGISSNH TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD GELHANLLCP VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY HKPHIPFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN PWMDIRQRED VQALNISVPY GPIPVDFQRK IRQSYFASVS YLDTQVGRLL SALDDLQLAN STIIAFTSDH GWALGEHGEW AKYSNFDVAT HVPLIFYVPG RTASLPEAGE KLFPYLDPFD SASQLMEPGR QSMDLVELVS LFPTLAGLAG LQVPPRCPVP SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF NPDEFLANFS DIHAGELYFV DSDPLQDHNM YNDSQGGDLF QLLMP (Disulfide bridge: 146-159, 397-407) |
Type |
Peptide |
Remark |
Therapeutic category: | 3959 |
|
Efficacy |
Lysosomal storage disease treatment, Enzyme replacement (iduronate-2-sulfatase) |
Type |
Enzyme replacement therapy product |
Comment |
Treatment of Hunter syndrome
|
Target |
|
Pathway |
|
Network |
nt06012 | Glycosaminoglycan degradation |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AB Enzymes
A16AB16 Idursulfase beta
D11025 Idursulfase beta (INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
395 Enzyme preparations
3959 Others
D11025 Idursulfase beta (INN); Idursulfase beta (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Sulfatases
IDS* [HSA_VAR:3423v1]
D11025 Idursulfase beta (INN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11025
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D11025
|
Other DBs |
|
LinkDB |
|